Epredia And Aiforia Announce Partnership For Global Distribution Of AI-powered Pathology Software
PR90197
PORTSMOUTH, N.H., June 21, 2021 /PRNewswire=KYODO JBN/--
Epredia, a global leader in precision cancer diagnostics, and Aiforia, a
medical software company providing Artificial Intelligence (AI) based solutions
for image analysis in pathology, have announced today that they have entered
into a commercial distribution agreement for Aiforia's comprehensive portfolio
of workflow enhancing solutions which enable pathologists to harness the power
of deep learning AI for image analysis.
Photo - https://mma.prnewswire.com/media/1537009/Clinical_Ki67_IA.jpg
Logo - https://mma.prnewswire.com/media/1458465/Epredia_Logo.jpg
Under the terms of this agreement, Epredia has been appointed as a global
distribution partner for Aiforia's portfolio of preclinical and clinical
pathology tools, including segment exclusivity for distribution in Japan,
Germany, UK, Italy, Spain, Sweden, Norway, Denmark, Iceland, France and the
USA. From Summer 2021, Epredia will begin to commercialize the Aiforia
portfolio of AI solutions. These solutions will be available as part of
Epredia's comprehensive digital pathology portfolio that already features the
best-in-class CE-marked 3DHistech P1000 WSI scanner*.
Aiforia aims to equip pathologists with AI-powered, secure, and scalable
cloud-based software for high precision image analysis that can be used in
preclinical research and clinical diagnostics. Their solutions aim to enhance
the speed and accuracy of pharmaceutical drug development and cancer
diagnostics using intuitive, AI-powered software. Aiforia's software currently
has over 3,000 pathologists and scientists as users in over 50 countries.
Aiforia recently announced the CE-IVD marking for its Clinical AI Model for
Breast Cancer: Ki67, a widely used key biomarker in breast cancer diagnostics,
as part of the company's upcoming Clinical Suites. The Aiforia Clinical Suites
are under development to support the diagnosis of some of the world's most
prevalent cancers such as breast, lung, prostate, and more. The Suites,
intended for release and regulatory filings over the coming years, are
portfolios of powerful tools enabling pathologists to harness the power of AI
to support them in accelerating sample review, enhancing diagnostic accuracy,
and ultimately in improving patient outcomes.
Aiforia's offering for preclinical assessment consists of bespoke AI model
development services backed by Aiforia's in-house science team using an
intuitive cloud-based platform, catering to a wide range of therapy areas. Over
400 AI models for preclinical research have already been developed using
Aiforia's solutions.
"This alliance with Aiforia to commercialize their highly innovative portfolio
of AI-based digital pathology solutions is another exciting step in building
our presence in this growing area of cancer diagnostics," explained John
Sweeney, President, Epredia. "We are pleased to be adding the Aiforia offering
to our portfolio of digital pathology solutions which now include cutting edge
AI software from the largest players in the field bundled with our portfolio of
best in class whole slide imaging scanners developed by 3DHistech. The product
development expertise of Aiforia that has gone into these solutions ideally
complements our global commercial reach and will enable us to bring their
solutions to more pathologists across the world."
"With their global presence in the pathology market and our expertise in
delivering AI-based solutions for pathologists, Epredia is the ideal commercial
partner to help us broaden the international reach of Aiforia's powerful AI
software to pathologists working in clinical diagnostics and preclinical drug
development," explained Jukka Tapaninen, Chief Executive Officer of Aiforia.
"Our mission is to become a global leader in AI-assisted image analysis to
improve the efficiencies of healthcare systems and enable better patient
outcomes."
* Regulatory requirements for the 3DHistech P1000 scanner and Aiforia's
pathology solutions vary by country, please consult with your commercial
partner to confirm the availability and approved use of the scanner and
Aiforia's pathology solutions in your country.
SOURCE: Epredia
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。